Bayer selects Pharmaron as partner organization

BayerBayer and Pharmaron have entered into a global collaboration agreement to develop new molecular entities for veterinary medicines. Under the collaboration, Bayer will fully leverage Pharmaron's Chemistry, Manufacturing and Controls (CMC) service platform. This will include drug substance and drug product manufacturing to support Bayer's research, development and commercialization needs. Financial terms were not disclosed.

Bayer and Pharmaron have agreed to jointly develop new molecular entities. Their goal is to provide veterinarians, pet owners and farmers with innovative therapies that address unmet medical needs of their animal patients. Pharmaron will provide state-of-the-art CMC capabilities and resources to accelerate the development of preclinical and clinical projects for Bayer Animal Health. Small molecules have always been the backbone of innovative drugs in veterinary medicines. The partnership between Bayer and Pharmaron will facilitate the exploration of the small molecule-based chemical space, aiming to offer a variety of future therapeutic options for diseases that still cannot be adequately treated today.

Dr. Douglas Hutchens, Bayer Animal Health’s Head of Drug Discovery, External Innovation & Chief Veterinary Officer, said: "Our collaboration is another example of how we realize our innovation strategy: By combining the know-how and capabilities from an industry leading Contract Development & Manufacturing Organization like Pharmaron with high quality innovation projects derived from Bayer’s research, we will reduce our time to market and increase our success rate to deliver our development portfolio to the market. We are constantly looking for innovative partners that enable us to bring our projects faster and improve probability for success in the animal health sector."

Dr. Boliang Lou, Chairman and CEO of Pharmaron commented: "Pharmaron's mission is to provide high quality R&D and commercialization services to the life sciences industry. We are very excited to form a strategic partnership with Bayer Animal Health, a world leading animal health company, to jointly develop innovative medicines for animals, by tapping into Pharmaron's CMC platform. We will work together to advance innovative products with high quality and an accelerated timeline, from discovery through development to commercialization."

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.

About Pharmaron

Pharmaron is a premier R&D service company supporting the life science industry. Founded in 2004, Pharmaron has invested in its people and facilities having established diverse drug R&D service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical & pharmaceutical development to clinical development. With operations in China, US and UK staffed by over 7,000 employees, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...